Integrated Solutions from Research to Commercialisation.
Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. 600+ companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.
Our vast range of services include:
Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA lab.
API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.
Pharmaceutical Development: Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.
Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.
Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.
Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.
Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.
Almac – Partnering to Advance Human Health™
Career opportunities: http://www.almacgroup.com/careers
Specialties
Pharmaceutical development services, Clinical trial supply & management, Diagnostics & biomarker discovery, API services & Chemical Development, Formulation & analytical development, Commercial manufacture, Genomic Services, Distribution
Almac Group Activity on LinkedIn
-
-
-
-
-
-
-
-
-
-
Almac Group has a new Project Group Leader - (New Products & Services)
Gary Dampman is now Project Group Leader - (New Products & Services), was Manager - Project Management Office at Apria Healthcare

